Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

Abbott NORTHAMPTON ... has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment ...

The company’s long-term investments in cutting-edge innovation, such as pulsed-field ablation, are beginning ... However, its key rivals like Abbott ABT and Boston Scientific BSX outperformed ...

Abbott What do you think of when you think about a job ... announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in ...

As of February 20, 2025, its stock price has risen 17.8% year-to-date, outperforming the broader medical sector and key competitors like Abbott ... emerging field of pulsed field ablation ...

The massive medtech company saw sales swell for its pulsed field ablation (PFA ... 19.5% on an organic basis in its most recent quarter. Abbott Laboratories, a health care and medtech company ...

Aims: Whether the intraprocedural anticoagulation regimen and activated clotting time (ACT) in pulsed field ablation (PFA ... or Advisor HD Grid Mapping Catheter, Abbott Laboratories, Chicago, IL) and ...

They also saw potential growth drivers in renal denervation, pulsed field ablation, the Diabetes business partnership with Abbott, and potential tailwinds for the spine business as Stryker leaves ...